Vitamin d and Qbrexza drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vitamin d (ergocalciferol) and Qbrexza (glycopyrronium tosylate). Common drug interactions include dry mouth among females and clumsiness among males.

The phase IV clinical study analyzes what interactions people have when they take Vitamin d and Qbrexza. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Vitamin d?

Vitamin d has active ingredients of ergocalciferol. It is often used in low vitamin d. eHealthMe is studying from 294,095 Vitamin d users. Check the latest studies of Vitamin d.

What is Qbrexza?

Qbrexza has active ingredients of glycopyrronium tosylate. eHealthMe is studying from 802 Qbrexza users. Check the latest studies of Qbrexza.

On Aug, 01, 2026

13 people who take Vitamin d and Qbrexza together, and have interactions are studied.

Vitamin d and Qbrexza drug interactions.

What are the common drug interactions of Vitamin D and Qbrexza, by gender? *:

female:

Dry mouth
Migraine (headache)
Loss of consciousness
Urinary retention (the inability to completely or partially empty the bladder)
Abdominal distension
Abdominal pain
Anxiety
Choking (mechanical obstruction of the flow of air from the environment into the lungs)
Constipation
Dehydration (dryness resulting from the removal of water)

male:

Clumsiness (a lack of coordination or elegance)
Dry mouth
Dry throat
Fall
Injection site discharge
Injection site pain
Pain
Sepsis (a severe blood infection that can lead to organ failure and death)

What are the common drug interactions of Vitamin D and Qbrexza, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Choking (mechanical obstruction of the flow of air from the environment into the lungs)
Dry mouth
Heart rate increased
Loss of consciousness
Presyncope
Tinnitus (a ringing in the ears)
Urinary retention (the inability to completely or partially empty the bladder)

30-39:

Mydriasis (a dilation of the pupil)
Vision blurred
Migraine (headache)
Dry mouth
Dry throat

40-49:

Mydriasis (a dilation of the pupil)
Vision blurred

50-59:

Clumsiness (a lack of coordination or elegance)
Fall
Infectious mononucleosis (infection usually caused by the epstein-barr virus)
Injection site discharge
Injection site pain
Malaise (a feeling of general discomfort or uneasiness)
Pain
Sepsis (a severe blood infection that can lead to organ failure and death)

60+:

Dry mouth
Oropharyngeal pain

What are the existing conditions these people have? *

Hyperhidrosis (abnormally increased sweating): 10 people, 76.92%
Stress And Anxiety: 1 person, 7.69%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 7.69%
Inflammation: 1 person, 7.69%
Hair Loss: 1 person, 7.69%
Drowsiness: 1 person, 7.69%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 1 person, 7.69%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 7.69%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 7.69%
Alopecia Areata (patchy baldness that typically begins with rapid hair loss): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Vitamin d and Qbrexza?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously